- Home
- CCNE vs SEPN Comparison
CCNE vs SEPN Comparison
Compare CCNE & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCNE
- SEPN
- Stock Information
- Founded
- CCNE 1865
- SEPN 2022
- Country
- CCNE United States
- SEPN United States
- Employees
- CCNE N/A
- SEPN N/A
- Industry
- CCNE Major Banks
- SEPN
- Sector
- CCNE Finance
- SEPN
- Exchange
- CCNE Nasdaq
- SEPN NYSE
- Market Cap
- CCNE 595.8M
- SEPN 631.0M
- IPO Year
- CCNE N/A
- SEPN 2024
- Fundamental
- Price
- CCNE $25.23
- SEPN $5.80
- Analyst Decision
- CCNE Hold
- SEPN Buy
- Analyst Count
- CCNE 1
- SEPN 4
- Target Price
- CCNE $28.00
- SEPN $34.00
- AVG Volume (30 Days)
- CCNE 83.9K
- SEPN 857.5K
- Earning Date
- CCNE 04-14-2025
- SEPN 02-28-2025
- Dividend Yield
- CCNE 2.85%
- SEPN N/A
- EPS Growth
- CCNE N/A
- SEPN N/A
- EPS
- CCNE 2.39
- SEPN N/A
- Revenue
- CCNE $217,361,000.00
- SEPN $981,000.00
- Revenue This Year
- CCNE N/A
- SEPN $406.62
- Revenue Next Year
- CCNE $17.56
- SEPN N/A
- P/E Ratio
- CCNE $10.56
- SEPN N/A
- Revenue Growth
- CCNE 0.09
- SEPN N/A
- 52 Week Low
- CCNE $17.74
- SEPN $4.17
- 52 Week High
- CCNE $29.29
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- CCNE 43.76
- SEPN N/A
- Support Level
- CCNE $25.90
- SEPN N/A
- Resistance Level
- CCNE $27.05
- SEPN N/A
- Average True Range (ATR)
- CCNE 0.66
- SEPN 0.00
- MACD
- CCNE -0.05
- SEPN 0.00
- Stochastic Oscillator
- CCNE 33.33
- SEPN 0.00
About CCNE CNB Financial Corporation
CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. In addition, the corporation provides wealth and asset management services, retirement plans and other employee benefit plans.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.